Meeting
2017 ASCO Annual Meeting
Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).
Authors
Charalambos Andreadis
University of California, San Francisco, San Francisco, CA
Charalambos Andreadis , Timothy S Fenske , Brian Thomas Hill , Patrick J. Stiff , David L. Grinblatt , Eric D. Hsi , Todd Kelley , Kristy L. Richards , Lale Kostakoglu , Heiko Schöder , Sin-Ho Jung , Brandy Pitcher , Kristen Pike , Teri Plona , Ryan Baugher , Stephanie Mellott , Nancy L. Bartlett , John Leonard , Thomas C. Shea , Steven Michael Devine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT02443077
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS7566)
DOI
10.1200/JCO.2017.35.15_suppl.TPS7566
Abstract #
TPS7566
Poster Bd #
328a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
First Author: Nancy L. Bartlett
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg
Poster
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
First Author: Mehdi Hamadani